Tech Company Financing Transactions
Cytovation Funding Round
On 4/23/2025, Cytovation announced $6 million in funding from Sandwater.
Transaction Overview
Company Name
Announced On
4/23/2025
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Undisclosed
Investors
Sandwater (Lead Investor)
Proceeds Purpose
These funds will be used to advance CY-101 into a multi-national Phase 2 clinical trial in patients with adrenocortical carcinoma due to start in late 2025 and with first clinical readouts expected in 2026. The trial will be conducted through a partnership between Cytovation, Cancer Research UK and the Norwegian Cancer Society under an agreement announced in January 2025 (click here for press release).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Solheimsgaten 11
Bergen, 5058
NO
Bergen, 5058
NO
Phone
Undisclosed
Website
Email Address
Overview
Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 4/23/2025: Coologics venture capital transaction
Next: 4/23/2025: Surfin venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs